MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma.

Citation:
de la Puente, P., B. Muz, A. Jin, F. Azab, M. Luderer, N. N. Salama, and A. K. Azab, "MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma.", Blood cancer journal, vol. 6, pp. e399, 2016 Feb 26.
PreviewAttachmentSize
salama-_blood_cancer_j_2016.pdf846.96 KB
Tourism